GlassScriptPhysician profile
Ann-Kristin Swahn
NPI 1710545603
$4,492.21
in general payments reported to CMS, 2019-2025
41 companies · $932 in 2025
The $932 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $720 · 2022: $967 · 2023: $861 · 2024: $1,011 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,805.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,016.12 | 2021-2025 | |
| Lilly USA, LLC | $608.41 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.39 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $250.65 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $242.19 | 2023-2025 | |
| Allergan, INC. | $221.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $189.54 | 2021-2025 | Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $174.96 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $169.82 | 2021-2025 | Wegovy |
| Axsome Therapeutics, INC. | $131.63 | 2023-2025 | Auvelity, Sunosi |
| Nestle Healthcare Nutrition INC. | $96.03 | 2021-2022 | |
| Amgen INC. | $93.00 | 2021-2025 | Evenity |
| Dynavax Technologies Corporation | $85.88 | 2022-2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $81.43 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $78.45 | 2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $62.34 | 2022-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $57.94 | 2021-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Organon LLC | $54.58 | 2022-2025 | Nexplanon |
| Janssen Pharmaceuticals, INC | $51.98 | 2021-2023 | Xarelto |
| Galderma Laboratories, L.P. | $50.22 | 2024-2025 | |
| Corium, LLC | $49.58 | 2023 | Azstarys, Adlarity |
| Takeda Pharmaceuticals U.S.A., INC. | $48.88 | 2021-2023 | Trintellix |
| Ironshore Pharmaceuticals INC. | $44.69 | 2024 | |
| Lundbeck LLC | $34.60 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $33.91 | 2021-2022 | |
| Harmony Biosciences LLC | $31.54 | 2025 | |
| Astellas Pharma US INC | $29.20 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $28.72 | 2025 | The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $28.04 | 2022-2023 | Quviviq |
| Impel Pharmaceuticals INC. | $25.99 | 2022-2023 | Trudhesa |
| Dexcom, INC. | $25.58 | 2024 | Dexcom G6 Transmitter |
| Biocryst US Sales Co., LLC | $19.72 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.75 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.41 | 2025 | |
| Xeris Pharmaceuticals, INC. | $16.22 | 2022 | |
| Noven Therapeutics, LLC | $14.95 | 2024 | Xelstrym |
| Antares Pharma, INC. | $13.70 | 2021 | |
| Exeltis, USA INC. | $13.63 | 2025 | Slynd |
| Sanofi Pasteur INC. | $11.07 | 2021 | |
| Phathom Pharmaceuticals, INC. | $8.36 | 2025 | Voquezna |
| Genentech USA, INC. | $6.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann-Kristin Swahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.